Interestingly, we found that individuals with high or intermediate probability of advanced liver fibrosis have an unfavorable cardio-vascular risk profile characterized by an increase in visceral adiposity, insulin resistance, inflammatory and pro-coagulant biomarkers such as hsCRP, erythrocyte sedimentation rate, and fibrinogen as well as lower levels of circulating IGF-1. The gene discussed is IGF1; the disease is Hepatic fibrosis.